These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 328295)

  • 21. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
    World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
    [No Abstract]   [Full Text] [Related]  

  • 22. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. General pharmaceutics--the new physical pharmacy.
    Fiese EF
    J Pharm Sci; 2003 Jul; 92(7):1331-42. PubMed ID: 12820138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability of drugs (first of two parts).
    Koch-Weser J
    N Engl J Med; 1974 Aug; 291(5):233-7. PubMed ID: 4600408
    [No Abstract]   [Full Text] [Related]  

  • 25. Differential thermal, solubility, and aging studies on various sources of digoxin and digitoxin powder: biopharmaceutical implications.
    Chiou WL; Kyle LE
    J Pharm Sci; 1979 Oct; 68(10):1224-9. PubMed ID: 512850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Possibilities and propositions of teaching biopharmacy in education of pharmacists].
    Kedvessy G
    Pharmazie; 1971 Nov; 26(11):655-6. PubMed ID: 5154314
    [No Abstract]   [Full Text] [Related]  

  • 27. Biopharmaceutical and physiocochemical studies on reserpine-polyvinylpyrrolidone coprecipitates.
    Stupak EI; Rosenberg HA; Bates TR
    J Pharmacokinet Biopharm; 1974 Dec; 2(6):511-24. PubMed ID: 4461781
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of drug metabolism in drug research and development: pharmaceutical chemistry aspects.
    Heimlich KR
    J Pharm Sci; 1972 Oct; 61(10):1686-9. PubMed ID: 5072432
    [No Abstract]   [Full Text] [Related]  

  • 29. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination.
    Schumacher GE
    Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265
    [No Abstract]   [Full Text] [Related]  

  • 30. [Analysis of the items of pharmaceutics of Chinese medicine accepted and supported by NSFC in recent 5 years].
    Han LW; Wang CE; Liu P; Ju DH
    Zhongguo Zhong Yao Za Zhi; 2004 Jan; 29(1):4-6. PubMed ID: 15709369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of the purity control of commercial bulk quinidine and hydroquinidine salts. NMR analysis and apparent partition coefficients.
    Huynh-Ngoc T; Sirois G
    Pharm Acta Helv; 1974; 49(1):37-40. PubMed ID: 4852368
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Solubilization in drug technology].
    Bashura GS; Kabachnyĭ GI; Pertsev IM
    Farm Zh; 1974; 29(5):26-35. PubMed ID: 4376986
    [No Abstract]   [Full Text] [Related]  

  • 34. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [On the pharmaceutical technology of film coating (author's transl)].
    Kala H; Dittgen M; Moldenhauer H; Zessin G
    Pharmazie; 1979 Nov; 34(11):755-65. PubMed ID: 397492
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Microcapsules, a new drug form].
    Lebedenko VIa; Griadunova GP; Dontsova GI
    Farmatsiia; 1979; 28(4):68-74. PubMed ID: 385354
    [No Abstract]   [Full Text] [Related]  

  • 38. [New formulations in dermatology].
    Fredon L; Mallard C
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S30-6. PubMed ID: 17563712
    [No Abstract]   [Full Text] [Related]  

  • 39. Practical considerations in development of solid dosage forms that contain cyclodextrin.
    Miller LA; Carrier RL; Ahmed I
    J Pharm Sci; 2007 Jul; 96(7):1691-707. PubMed ID: 17243148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biopharmacy].
    Modrzejewski F
    Pharmazie; 1971 Nov; 26(11):661. PubMed ID: 5154318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.